The results of prostate cancer screening and the problem of the hyperdiagnosis of the disease in the Republic of Belarus
https://doi.org/10.17650/1726-9776-2016-12-1-58-62
Abstract
The prostate cancer (PC) screening program elaborated in the Republic of Belarus, which envisages the determination of prostate-specific antigen (PSA) levels once every two years among 50–65-year-old men and 6-point lateralized transrectal ultrasound-guided biopsy at a PSA level of > 4.0 ng / ml, could rule out the probability of diagnosing clinically insignificant PC. Out of 20,786 male examinees, 249 (1.2 %) patients were found to have PC. Of them, 190 patients underwent D»Amico cancer risk stratification. A low-risk group included 11 (5.6 %) patients, for whom follow-up tactics might be selected; the other patients should receive appropriate treatment. Therefore, the problem of hyperdiagnosis is not relevant during the first PC screening round in Belarus and cannot constrain the further introduction of the screening program.
About the Authors
S. A. Krasnyi
N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology
Belarus
Lesnoy Settlement, Minsk District 223040
Belarus
Lesnoy Settlement, Minsk District 223040
D. T. Tarend
Minsk Regional Clinical Hospital
Belarus
Lesnoy Settlement, Minsk District 223041
Belarus
Lesnoy Settlement, Minsk District 223041
S. A. Semenov
N.N. Aleksandrov Republican Research and Practical Center for Oncology and Medical Radiology
Belarus
Lesnoy Settlement, Minsk District 223040
Belarus
Lesnoy Settlement, Minsk District 223040
References
1. Океанов А.Е., Моисеев П.И., Левин Л.Ф. Статистика онкологических заболеваний в Республике Беларусь (2004–2013). Минск: РНПЦ ОМР им. Н.Н. Александрова, 2014. 382 с. [Оkeanov А.Е., Моiseev P.I., Levin L.F. Statistics of oncologic diseases in the Republic of Belarus (2004-2013). Ed. by О.G. Sukonkо. Мinsk: N.N. Alexandrov RSPC ОМR, 2014. 382 p. (In Russ.)].
2. Sakr W.A., Grignon D.J., Haas.G.P. et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996;30:138–44.
3. Donovan J.L. Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring. J Natl Cancer Inst Monogr 2012:191–96.
4. Sandhu G.S., Andriole G.L. Overdiagnosis of prostate cancer. J Natl Cancer Inst Monogr 2012:146–51.
5. Neal D.E., Donovan J.L., Martin R.M. et al. Screening for prostate cancer remains controversial. Lancet 2009;374:1482–3.
6. Heidenreich A., Abrahamsson P.-A., Artibani W. et al. Early detection of prostate cancer: European Association of Urology Recommendation. Eur Urol 2013;l64:347–54.
7. Dall’Era M.A., Albertsen P.C., Bangma C. et al. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 2012;62(6):976–83.
8. Heijnsdijk E.A., Wever E.M., Auvinen A. et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:595–605.
Review
For citations:
Krasnyi S.A., Tarend D.T., Semenov S.A. The results of prostate cancer screening and the problem of the hyperdiagnosis of the disease in the Republic of Belarus. Cancer Urology. 2016;12(1):58-62. https://doi.org/10.17650/1726-9776-2016-12-1-58-62
Views:
1445
Email this article 